Loading...
Some recent studies suggest that colchicine may reduce cardiac events, presumably through its anti-inflammatory properties. In the CLEAR study (NCT03048825), more than 7000 individuals were randomized to receive colchicine or placebo (as well as spironolactone or placebo, in a 2×2 factorial design) after myocardial infarction. The investigators have reported colchicine trial results.
During a median follow-up of 3 years, a combined outcome of cardiovascular death, myocardial infarction, stroke, or unplanned revascularization was similar between the two groups (9.1% in the colchicine group and 9.3% in the placebo group). Moreover, C-reactive protein level, a measure of inflammation, was lower in the colchicine group at 3 months (2.98 mg/L vs.…